A Phase II Study of Lenalidomide (Revlimid) as Second Line Therapy in Patients With Chronic Graft-Versus-Host Disease (GVHD).
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2013
At a glance
- Drugs Lenalidomide (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 24 Aug 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 02 May 2011 Planned End Date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 13 Dec 2010 Planned End Date changed from 1 Apr 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.